



02-22-2002

U.S. Patent & TMO/TM Mail Rcpt Dt. #58

PATENT

Case Docket No. ALLIA.143C1

Date: February 19, 2002

Page 1

In re application of H. Zaghouani
App. No. 09/623,728
Filed January 22, 2001
For COMPOUNDS, COMPOSITIONS
AND METHODS FOR THE
ENDOCYTIC PRESENTATION
OF IMMUNOSUPPRESSIVE
FACTORS
Examiner : Unknown
Art Unit : 1615

I hereby certify that this correspondence and all marked
attachments are being deposited with the United States
Postal Service as first class mail in an envelope addressed
to: United States Patent and Trademark Office, P.O. Box
2327, Arlington, VA 22202, on

February 19, 2002

(Date)

Daniel Hart, Reg. No. 40,637

TECH CENTER 1600/2900

MAR 01 2002

RECEIVED

UNITED STATES PATENT AND TRADEMARK OFFICE
P.O. Box 2327
Arlington, VA 22202

Sir:

Transmitted herewith is a supplemental preliminary amendment in the above-identified application.

- (X) The present application qualifies for small entity status under 37 C.F.R. § 1.27.
- (X) Return prepaid postcard.
- (X) Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Daniel Hart
Registration No. 40,637
Attorney of Record

ALLIA.143C1



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : H. Zaghouani
Appl. No. : 09/623,728
Filed : January 22, 2001
For : COMPOUNDS, COMPOSITIONS
AND METHODS FOR THE
ENDOCYTIC PRESENTATION
OF IMMUNOSUPPRESSIVE
FACTORS
Examiner : Unknown

Group Art Unit: 1615

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: United States Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202

February 19, 2002
(Date)

Daniel Hart, Reg. No. 40,637

TECH CENTER 1600-2900

MAR 01 2002

RECEIVED

SUPPLEMENTAL PRELIMINARY AMENDMENT

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

Prior to the examination of the above-identified application on the merits, please amend the application as follows:

IN THE CLAIMS:

1. (Amended) A fusion protein for the alleviation of symptoms associated with an autoimmune disorder comprising an immunoglobulin or portion thereof linked to one or more autoantigenic polypeptides or fragments thereof wherein said immunoglobulin or portion thereof is capable of binding to an Fc receptor and being endocytosed by an antigen presenting cell and said one or more autoantigenic polypeptides or fragments thereof is derived from a protein responsible for an autoimmune disease and provides at least one T cell receptor peptide agonist for presentation on the surface of said antigen presenting cell upon endocytic processing.